Ansa will be initiating an Early Access Program for clonal synthetic genes in April 2023Readmore
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
9 MAR
2023
Ansa will be initiating an Early Access Program for clonal synthetic genes in April 2023Readmore
11 December
2023
Advancing AOCs to transform the delivery of RNA therapeutics
Recent clinical advances and product approvals have demonstrated significant progress in the development of first-generation RNA therapeutics, for instance with antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs).Readmore
October 8th
2023
Fostering the Next Generation of Antisense Oligonucleotide Therapies
Antisense oligonucleotides (ASOs) have faced their share of challenges, but a combination of research advances and a market ripe for innovation is setting this drug class up for a resurgence. Antisense oligonucleotide (ASO)—a class of drugs that works bReadmore
24 Apr
2023
UMass Chan scientists deliver siRNA therapy to lung
Delivery technology successfully blocks SARS-CoV-2 infection in mice; adaptable for multiple diseasesReadmore
21 Aug
2023
Qalsody is an antisense oligonucleotide that targets SOD1 mRNA
FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosisReadmore
Feb 22
2022
Ansa Biotechnologies Achieves Breakthrough in DNA Synthesis
Ansa Biotechnologies is also launching an Early Access Program aimed at helping researchers obtain synthetic genes with sequences that were previously challenging to synthesizeReadmore
Feb 22
2022
Secarna’s LNAplusTM antisense oligonucleotides (ASOs) combined with Denali’s Oligonucleotide Transport Vehicle (OTV) technology provide potential for novel therapies in the area of difficult-to-treat central nervous system (CNS) diseasesReadmore
7 Jun
2023
Ansa Biotechnologies Inc., the company developing a new way to make DNA using enzymes, is announcing a partnership with TeselaGen Biotechnology IncReadmore
Aug 07
2023
Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger
The RNA-edited therapy developer prepares to combine with Frequency Therapeutics, focusing initially on liver and CNS disordersReadmore
4 JAN
2023
Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleoReadmore
27Mar
2023
Discovery and development of innovative therapeutics for the treatment of neurological diseases, today announced the signature of a multi-target research and option agreement. Within the collaboration, the companies will work together to generate novel ASReadmore
27 FEB
2023
Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company developing RNA-based therapeutics that address important unmet medical needs, today announced that it has filed a provisional patent application with the United States Patent and Trade Office (USPTO) to Readmore
18May
2023
GenScript Expands Peptide and Oligonucleotide Production Facility in China
GenScript’s new life-science building in China; facilities offer fast-turnaround, high-purity oligonucleotide and peptide synthesis service for R&D and preclinical applicationsReadmore
16MAY
2023
Chinook Therapeutics partners with Ionis Pharmaceuticals to advance precision medicine for rare kidney disease. Leveraging Chinook’s expertise in nephrology and Ionis’ RNA-targeted therapeutics, the collaboration aims to develop an antisense oligonuclReadmore
12 APR
2023
UMass Chan scientists deliver siRNA therapy to lung
Scientists at UMass Chan Medical School have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease. Readmore
31May
2023
RNA fusions can be used as biomarkers to identify cancer sub-types and monitor for residual diseaseReadmore
10 Jul
2023
SAN DIEGO,Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, announced today a research collaboration agreement with GSK plc (LSE/NYSE: GSK) to advance the discovery and development of ElReadmore
31 JAN
2023
Aptamer Group partner with BaseCure Therapeutics to develop new targeted gene therapies
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies.Readmore
20 JAN
2023
ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324
ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).Readmore